Background: The use of antipsychotics, especially second-generation antipsychotics (SGAs), for children with mental health disorders in Canada has increased dramatically over the past five years. These medications have the potential to cause major metabolic and neurological complications with chronic use.
Objective: To synthesize the evidence for specific metabolic and neurological side effects associated with the use of SGAs in children, and provide evidence-based recommendations for the monitoring of these side effects.
Methods: A systematic review of controlled clinical trials of SGAs involving children was performed. Recommendations for monitoring SGA safety were made according to a classification scheme based on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. When there was inadequate evidence, recommendations were based on consensus and expert opinion. A multidisciplinary consensus group reviewed all relevant evidence and reached consensus on the recommendations.
Results: The present guidelines provide evidence-based recommendations for monitoring SGA safety. The strength of recommendations for specific physical examination manoeuvres and laboratory tests are provided for each SGA medication at specific time points.
Conclusion: Multiple randomized controlled trials evaluated the efficacy of many of the SGAs in paediatric mental health disorders. These benefits, however, are not without risks - both metabolic and neurological side effects occur in children treated with SGAs. The risk of weight gain, increased body mass index and abnormal lipid levels is greatest with olanzapine, followed by clozapine and quetiapine. The risk of neurological side effects of the treatment is greatest with risperidone, olanzapine and aripiprazole. Appropriate monitoring procedures for adverse effects will improve the quality of care of children treated with these medications.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223902 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Background: In Alzheimer's Disease trials, the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR) are commonly utilized as inclusionary criteria at screening. These measures, however, do not always reaffirm inclusionary status at baseline. Score changes between screening and baseline visits may imply potential score inflation at screening leading to inappropriate participant enrollment.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
School of Medicine, Johns Hopkins University, and Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.
Background: Agitation is a common and disabling symptom of Alzheimer's dementia (AD). Pharmacological treatments are recommended if agitation is not responsive to psychosocial intervention. Citalopram was effective in treating agitation in AD but was associated with cognitive and cardiac risks linked to its R- but not S-enantiomer.
View Article and Find Full Text PDFDementia Care Practice.
Alzheimers Dement
December 2024
Ontario Shores Centre for Mental Health Sciences, Whitby, ON, Canada.
Background: Neuropsychiatric symptoms (NPS) of dementia are a heterogenous group of non-cognitive symptoms and behaviors that occur in up to 90% of individuals with the condition. Characterizing NPS is a major issue and current methods are unreliable as they rely on subjective observations. Automatic identification of behaviors using central and peripheral physiological markers may be helpful to detect behaviors, allow for early intervention, and prevent critical incidents in patients with dementia.
View Article and Find Full Text PDFEvaluation of Depression and Cognitive Status in Geriatric Patients Undergoing Orthopedic Surgery.
Acta Chir Orthop Traumatol Cech
January 2025
Department of Orthopaedics and Traumatology, Faculty of Medicine, Kütahya Health Sciences University, Kütahya, Turkey.
Purpose Of The Study: Cognitive disorders are common in geriatric surgical patients We conducted a study to evaluate depression and cognitive behavior in geriatric patients undergoing orthopedic surgery.
Material And Methods: This descriptive cross-sectional study was conducted at a university hospital in Turkey, involving 262 elderly patients who underwent orthopedic surgeries. Data were collected using The Patient Information Form, Standardized Mini-Mental Test, and Geriatric Depression Scale.
The Index of Cannabis Equivalence (ICE): A User-Centered Approach to Standardization of Cannabis Dose-Response.
J Psychoactive Drugs
January 2025
Department of Psychology, The University of British Columbia, Kelowna, BC, Canada.
The increasing acceptance of cannabis use, and policy changes in several jurisdictions has led researchers and public health experts to call for a standard cannabis dose. Standard dosing units are useful tools for regulation, substance use guidelines, data collection, consistency of research, as a means of communicating low-risk recommendations and dose-related effects, and for self-monitoring. Efforts to standardize cannabis dose have focused on cannabinoid content without considering tolerance or mode.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!